Literature DB >> 11403365

Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment Study. HOT Study Group.

A Zanchetti1, L Hansson, B Dahlöf, D Elmfeldt, S Kjeldsen, R Kolloch, P Larochelle, G T McInnes, J M Mallion, L Ruilope, H Wedel.   

Abstract

BACKGROUND: The Hypertension Optimal Treatment (HOT) Study has provided information about cardiovascular events in 18790 hypertensives, subjected to pronounced blood pressure (BP) lowering for a mean of 3.8 years. The HOT study data have subsequently been analysed after stratification of the patients according to global cardiovascular risk, and it has been found that, despite intensive blood pressure lowering in all risk strata, morbid event rates increased with increasing risk stratum.
OBJECTIVES: Previously analysed global risk strata were based on combinations of risk factors. The analyses presented here were intended to provide information on the relative role that the presence of each individual factor may have in increasing cardiovascular risk, despite good BP control.
METHODS: Risk ratios (RR) for patients with and those without a risk factor were calculated with 95% confidence intervals (CI) using a Cox proportional hazard model, and adjusted for all variables except the one under examination.
RESULTS: For all risk factors considered and for all types of event, RR were always greater than 1, indicating a greater risk in the presence, compared with that in the absence of each factor. The male gender was a statistically significant risk for cardiovascular (CV) events, CV and total mortality and particularly for myocardial infarction (MI); age > or = 65 years for CV events, stroke, CV and particularly total mortality; smoking for all events analysed, but particularly for total mortality (twice higher in smokers than in non-smokers); high serum cholesterol (> 6.8 mmol/l) for CV events, MI and CV mortality; high serum creatinine (> 155 micromol/l) for CV events, stroke, CV and total mortality; diabetes for CV events, stroke, total mortality and particularly CV mortality; and ischaemic heart disease for all events analysed. Adjusted RR were often close to or greater than 2.
CONCLUSIONS: Each of the risk factors considered was found to be an important cause of residual risk, despite good BP control. These findings emphasize the importance of addressing other correctable risk factors, e.g. smoking, hypercholesterolaemia and diabetes, as well as rigorous control of blood pressure, and of initiating antihypertensive therapy before cardiovascular and renal damage becomes manifest.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11403365     DOI: 10.1097/00004872-200106000-00021

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  22 in total

1.  JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice.

Authors: 
Journal:  Heart       Date:  2005-12       Impact factor: 5.994

Review 2.  What is the ideal blood pressure goal for patients with stage III or higher chronic kidney disease?

Authors:  Yazan Khouri; Susan P Steigerwalt; Mershed Alsamara; Peter A McCullough
Journal:  Curr Cardiol Rep       Date:  2011-12       Impact factor: 2.931

Review 3.  Cardiac myocyte-fibroblast interactions and the coronary vasculature.

Authors:  Stephanie L K Bowers; Troy A Baudino
Journal:  J Cardiovasc Transl Res       Date:  2012-09-18       Impact factor: 4.132

4.  Morning blood pressure at home predicts erythropoietin-induced hypertension in patients with chronic renal diseases.

Authors:  Satoru Kuriyama; Yasushi Otsuka; Rinako Iida; Kei Matsumoto; Tatsuo Hosoya
Journal:  Clin Exp Nephrol       Date:  2007-03-28       Impact factor: 2.801

5.  Cost-Utility Analysis of Bariatric Surgery in Italy: Results of Decision-Analytic Modelling.

Authors:  Marcello Lucchese; Oleg Borisenko; Lorenzo Giovanni Mantovani; Paolo Angelo Cortesi; Giancarlo Cesana; Daniel Adam; Elisabeth Burdukova; Vasily Lukyanov; Nicola Di Lorenzo
Journal:  Obes Facts       Date:  2017-06-10       Impact factor: 3.942

6.  [Effects of a structured exercise programme on cardiovascular risk programmes in post-menopausal women. CLIDERICA study].

Authors:  Pedro Saucedo Rodrigo; José Abellán Alemán; Purificación Gómez Jara; Mariano Leal Hernández; Enrique Ortega Toro; Juan Carlos Colado; Juan Carlos Colado Sánchez; Pilar Sáinz de Baranda Andújar
Journal:  Aten Primaria       Date:  2008-07       Impact factor: 1.137

7.  The kaiser permanente northwest cardiovascular risk factor management program: a model for all.

Authors:  Jodi S Joyce; Martina M Fetter; Dean H Klopfenstein; Michael K Nash
Journal:  Perm J       Date:  2005

8.  Amlodipine added to quinapril vs quinapril alone for the treatment of hypertension in diabetes: the Amlodipine in Diabetes (ANDI) trial.

Authors:  Sheldon Tobe; Kalina Kawecka-Jaszcz; Faiez Zannad; George Vetrovec; Rajiv Patni; Harry Shi
Journal:  J Clin Hypertens (Greenwich)       Date:  2007-02       Impact factor: 3.738

9.  Effects of monotherapy and combination therapy on blood pressure control and target organ damage: a randomized prospective intervention study in a large population of hypertensive patients.

Authors:  Michele Adolfo Tedesco; Francesco Natale; Raffaele Calabrò
Journal:  J Clin Hypertens (Greenwich)       Date:  2006-09       Impact factor: 3.738

10.  Guideline adherence in cardiovascular risk assessment and analysis in 15,000 hypertensive German patients in real life: results of the Prospective 3A Registry.

Authors:  Ralf Dechend; Edelgard Kaiser; Wolfgang Derer; Evelin Deeg; Andreas Busjahn; Roland E Schmieder; Uwe Zeymer
Journal:  J Clin Hypertens (Greenwich)       Date:  2012-05-31       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.